Angiotensin receptor neprilysin inhibitor (Formulary)

SACUBITRIL/VALSARTAN

Important: Therapy notes

  • If the patient is already on an ACE inhibitor, it should be stopped for 36 hours before initiating sacubitril/valsartan to minimise the risk of angioedema.

Important: Formulation and dosage details

Formulation:

Tablets 24mg/26mg, 49mg/51mg, 97mg/103mg (Entresto®) (s)

Dosage:

Patients with heart failure who remain symptomatic despite optimal medical therapy with an ejection fraction less than 40% (equivalence to severe or moderate – severe LV systolic dysfunction), 49mg/51mg twice daily, increased at 2 to 4 weeks to the target dose of 97mg/103mg twice daily as tolerated.
Refer to SPC for details of patients for whom a lower starting dose is recommended.

Editorial Information

Document Id: F046